Showing results (1-10 of 143) with videos related to
Sort By:
Pageof 15
Acta Physiologica (Oxford, England)|May 30, 2020
An update on ACE2 amplification and its therapeutic potentialAlonso Marquez, Jan Wysocki, Jay Pandit, et al.Kidney International|September 24, 2019
Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?Alonso Marquez, Daniel BatlleThescientificworldjournal|September 6, 2005
Angiotensin II and renal tubular ion transportPatricia Valles, Jan Wysocki, Daniel BatlleClinical Science (London, England : 1979)|November 2, 2020
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discoveryEnrique Lores, Jan Wysocki, Daniel BatlleHypertension (Dallas, Tex. : 1979)|December 3, 2024
ACE2, From the Kidney to SARS-CoV-2: Donald Seldin Award Lecture 2023Daniel Batlle, Luise Hassler, Jan WysockiBiomolecules|December 22, 2019
Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin SystemJan Wysocki, Arndt Schulze, Daniel BatlleClinical Science (London, England : 1979)|March 14, 2020
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?Daniel Batlle, Jan Wysocki, Karla SatchellAmerican Journal of Hypertension|May 14, 2015
Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III AxisJan Wysocki, Minghao Ye, Daniel BatllePhysiological Reports|December 15, 2018
Apelinergic system in the kidney: implications for diabetic kidney diseaseTilman Müller, Anastasia Z Kalea, Alonso Marquez, et al.Current Opinion in Nephrology and Hypertension|April 15, 2008
New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathyDaniel Batlle, María José Soler, Jan WysockiPageof 15